Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.

The American journal of pathology - 1 May 2017

Sim Sung Hoon, Kim Soyeon, Kim Tae Min, Jeon Yoon Kyung, Nam Soo Jeong, Ahn Yong-Oon, Keam Bhumsuk, Park Hyun Ho, Kim Dong-Wan, Kim Chul Woo, Heo Dae Seog

Abstract excerpt

Inhibition of the Janus kinase (JAK)-STAT pathway has been implicated as a treatment option for extranodal natural killer/T-cell lymphoma, nasal type (NTCL). However, JAK-STAT pathway alterations in NTCL are variable, and the efficacy of JAK-STAT pathway inhibition has been poorly evaluated. JAK3 mutation and STAT3 genetic alterations were investigated by direct sequencing and immunohistochemistry in 84 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Janus Kinase 3
Share to Nose Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperidines

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Pyrroles

Share to STAT3 Transcription Factor

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 28284718
DOI: 10.1016/j.ajpath.2017.01.004

Genes

JAK3
STAT3
SRC

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.PMID 28284718Read ↗

JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.Semantic proximity Read ↗

Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.Semantic proximity Read ↗

Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.Semantic proximity Read ↗

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.Semantic proximity Read ↗

Frequent <i>BCOR</i> aberrations in extranodal <scp>NK/T</scp>‐Cell lymphoma, nasal typeSemantic proximity Read ↗

Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphomaSemantic proximity Read ↗

JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.Semantic proximity Read ↗

Natural killer/T-cell lymphomas in pediatric and adolescent patients.Semantic proximity Read ↗

The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumoursSemantic proximity Read ↗

STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia.Semantic proximity Read ↗

An immunoevasive strategy through clinically-relevant pan-cancer genomic and transcriptomic alterations of JAK-STAT signaling components.Semantic proximity Read ↗

Mutations in the JAK / STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T‐cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.